257 related articles for article (PubMed ID: 32757789)
1. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors.
Mollica V; Maggio I; Lopez-Beltran A; Montironi R; Cimadamore A; Cheng L; Rizzo A; Giunchi F; Schiavina R; Fiorentino M; Brunocilla E; Massari F
Expert Rev Anticancer Ther; 2020 Sep; 20(9):755-763. PubMed ID: 32757789
[TBL] [Abstract][Full Text] [Related]
2. Urothelial carcinoma: the development of FGFR inhibitors in combination with immune checkpoint inhibitors.
Qin Q; Patel V; Galsky MD
Expert Rev Anticancer Ther; 2020 Jun; 20(6):503-512. PubMed ID: 32436413
[TBL] [Abstract][Full Text] [Related]
3. The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.
Liu ST; Hui G; Mathis C; Chamie K; Pantuck AJ; Drakaki A
Clin Genitourin Cancer; 2018 Apr; 16(2):e269-e276. PubMed ID: 29199023
[TBL] [Abstract][Full Text] [Related]
4. TALASUR trial: a single arm phase II trial assessing efficacy and safety of TALazoparib and Avelumab as maintenance therapy in platinum-Sensitive metastatic or locally advanced URothelial carcinoma.
Coquan E; Clarisse B; Lequesne J; Brachet PE; Nevière Z; Meriaux E; Bonnet I; Castera M; Goardon N; Boutrois J; Travers R; Joly F; Grellard JM; Thiery-Vuillemin A
BMC Cancer; 2022 Nov; 22(1):1213. PubMed ID: 36434554
[TBL] [Abstract][Full Text] [Related]
5. Durvalumab in urothelial cancers.
Lavaud P; Hamilou Z; Loriot Y; Massard C
Expert Rev Anticancer Ther; 2018 Apr; 18(4):311-318. PubMed ID: 29486607
[TBL] [Abstract][Full Text] [Related]
6. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
Montazeri K; Sonpavde G
Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
[TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for urothelial (bladder) cancer.
Cumberbatch K; He T; Thorogood Z; Gartrell BA
Expert Opin Emerg Drugs; 2017 Jun; 22(2):149-164. PubMed ID: 28556678
[TBL] [Abstract][Full Text] [Related]
8. Management of Muscle-Invasive Urothelial Cancer and the Emerging Role of Immunotherapy in Advanced Urothelial Cancer.
Giridhar KV; Kohli M
Mayo Clin Proc; 2017 Oct; 92(10):1564-1582. PubMed ID: 28982487
[TBL] [Abstract][Full Text] [Related]
9. Latest evidence on clinical outcomes and prognostic factors of advanced urothelial carcinoma in the era of immune checkpoint inhibitors: a narrative review.
Taguchi S; Kawai T; Nakagawa T; Kume H
Jpn J Clin Oncol; 2024 Mar; 54(3):254-264. PubMed ID: 38109484
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant PARPi for urothelial carcinoma: between lifeline and desperation.
Tayeh GA; Alkassis M; Semaan A; Khalil N; Nemr E; Waked C
Future Oncol; 2021 Sep; 17(25):3281-3283. PubMed ID: 34287018
[No Abstract] [Full Text] [Related]
11. The emerging role of antibody-drug conjugates in urothelial carcinoma.
Lattanzi M; Rosenberg JE
Expert Rev Anticancer Ther; 2020 Jul; 20(7):551-561. PubMed ID: 32552213
[TBL] [Abstract][Full Text] [Related]
12. Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: a meta-analysis.
Rizzo A; Mollica V; Santoni M; Ricci AD; Gadaleta-Caldarola G; Montironi R; Massari F
Future Oncol; 2022 Feb; 18(6):739-748. PubMed ID: 35048736
[No Abstract] [Full Text] [Related]
13. [Precision oncology options in urological cancers].
Franz A; Plage H; Fendler A; Schlomm T; Kornienko K
Urologie; 2023 Jul; 62(7):696-704. PubMed ID: 37294331
[TBL] [Abstract][Full Text] [Related]
14. Combination Therapy With Immune Checkpoint Inhibitors in Urothelial Carcinoma: Current Data and Future Outlook.
Feng Z; Vuky J
Oncology (Williston Park); 2021 Jul; 35(7):410-420. PubMed ID: 34264569
[TBL] [Abstract][Full Text] [Related]
15. [Systemic chemotherapy for transitional cell carcinoma of the urothelium].
Lehmann J; Retz M; Hack M; Siemer S; Stöckle M
Onkologie; 2003 Oct; 26 Suppl 4():18-25. PubMed ID: 14605452
[TBL] [Abstract][Full Text] [Related]
16. Docetaxel for the treatment of bladder cancer.
Albany C; Sonpavde G
Expert Opin Investig Drugs; 2015; 24(12):1657-64. PubMed ID: 26535615
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness of Immune Checkpoint Inhibitors in Patients with Platinum Refractory Advanced Urothelial Carcinoma.
Swami U; Haaland B; Kessel A; Nussenzveig R; Maughan BL; Esther J; Sirohi D; Pal SK; Grivas P; Agarwal N
J Urol; 2021 Mar; 205(3):709-717. PubMed ID: 33080152
[TBL] [Abstract][Full Text] [Related]
18. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
Mehta R; Wood AC; Yu J; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):451-461. PubMed ID: 33660569
[No Abstract] [Full Text] [Related]
19. [Current developments in the medical treatment of advanced urothelial carcinoma of the bladder].
Schmid SC; Gschwend JE; Retz M;
Aktuelle Urol; 2014 Jan; 45(1):55-63; quiz 64-5. PubMed ID: 24500963
[TBL] [Abstract][Full Text] [Related]
20. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial.
Petrylak DP; de Wit R; Chi KN; Drakaki A; Sternberg CN; Nishiyama H; Castellano D; Hussain S; Fléchon A; Bamias A; Yu EY; van der Heijden MS; Matsubara N; Alekseev B; Necchi A; Géczi L; Ou YC; Coskun HS; Su WP; Hegemann M; Percent IJ; Lee JL; Tucci M; Semenov A; Laestadius F; Peer A; Tortora G; Safina S; Del Muro XG; Rodriguez-Vida A; Cicin I; Harputluoglu H; Widau RC; Liepa AM; Walgren RA; Hamid O; Zimmermann AH; Bell-McGuinn KM; Powles T;
Lancet; 2017 Nov; 390(10109):2266-2277. PubMed ID: 28916371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
